Agenus shared on LinkedIn:
“Preparations for Phase 3 ROBBIN are moving forward.
Following ESMO, our medical team traveled to São Paulo, Brazil, where a packed room of investigators and trial site teams came together to prepare for the study’s planned opening in Q1 2027.
The meeting reflects the work underway with sites around the world as we prepare to evaluate botensilimab and balstilimab before surgery in patients with high-risk, localized MSS colon cancer.
Thank you to the investigators, site teams and our colleagues for the energy and dedication they bring to this effort.
Each meeting advances the preparation needed to bring ROBBIN to patients.”
Proceed to the video attached to the post.
You may also be interested in:
